Abbott Secures EUA for COVID-19 Combination Test

Abbott has received Emergency Use Authorization (EUA) from the FDA for its Alinity m Resp-4-Plex molecular assay, a combination test for SARS-CoV-2, Influenza A and B, and respiratory syncytial virus (RSV).

The test uses either an anterior nasal or nasopharyngeal swab collected by a healthcare provider or an anterior nasal swab self-collected at a healthcare location for patients suspected of COVID-19 infection.

The assay runs on the company’s Alinity m system, a polymerase chain reaction (PCR) platform that offers a turnaround time for assays of less than 115 minutes.